The professor of molecular geriatrics at Uppsala University talked about the research journey that led to the development of targeted antibody therapies for Alzheimer disease and emphasized the need for early diagnosis. [WATCH TIME: 5 minutes]
Lars Lannfelt, MD, PhD
Advertisement
Professor of molecular geriatrics at Uppsala University.
Articles by Lars Lannfelt, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology
2
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
3
Phase 2 OPAL Study to Test Muscle-Targeting Therapy Apitegromab in Infants With SMA
4
Decision-Making in De-Escalating Therapy for Multiple Sclerosis
5
